Home
ABBV
ABBV News

Latest AbbVie Inc. (ABBV) News on October 23, 2025

This 3 Stocks Portfolio Provides Monthly Income

Zacks

2 days ago

This 3 Stocks Portfolio Provides Monthly Income

Top Stock Reports for Apple, Meta Platforms & JPMorgan

Zacks

2 days ago

Top Stock Reports for Apple, Meta Platforms & JPMorgan

AbbVie's Rinvoq Beats Humira in Key Arthritis Trial

GuruFocus.com

2 days ago

AbbVie's Rinvoq Beats Humira in Key Arthritis Trial

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

PR Newswire

2 days ago

The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients

Uncovering 3 Stocks Including Palo Alto Networks That May Be Trading Below Intrinsic Value Estimates

Simply Wall St.

2 days ago

Uncovering 3 Stocks Including Palo Alto Networks That May Be Trading Below Intrinsic Value Estimates

MT Newswires

2 days ago

BMO Capital Adjusts Price Target on AbbVie to $258 From $240, Maintains Outperform Rating

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

Zacks

3 days ago

Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings

MT Newswires

3 days ago

AbbVie Says Upadacitinib Shows Superior Efficacy Over Humira in Late-Stage Rheumatoid Arthritis Trial

AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin

TipRanks

5 days ago

AbbVie completes acquisition of Gilgamesh Pharmaceuticals’ bretisilocin

MT Newswires

6 days ago

Sector Update: Health Care Stocks Mixed Friday Afternoon

MT Newswires

6 days ago

Novo Nordisk Hires AbbVie Executive as Trump Mounts Pricing Pressure

MT Newswires

6 days ago

AbbVie Closes Bretisilocin Acquisition

MT Newswires

6 days ago

Raymond James Adjusts Price Target on AbbVie to $250 From $236, Maintains Outperform Rating

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

PR Newswire

6 days ago

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

3 Stocks Trading At Discounts Of Up To 48.8% Below Estimated Intrinsic Value

Simply Wall St.

7 days ago

3 Stocks Trading At Discounts Of Up To 48.8% Below Estimated Intrinsic Value

Calico Appoints Philip R. Kym, Ph.D., as Head of Drug Discovery

PR Newswire

7 days ago

Calico Appoints Philip R. Kym, Ph.D., as Head of Drug Discovery

October 2025 Value Picks: 3 Stocks That May Offer Attractive Valuations

Simply Wall St.

7 days ago

October 2025 Value Picks: 3 Stocks That May Offer Attractive Valuations

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.

Motley Fool

7 days ago

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.

Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV)

Insider Monkey

7 days ago

Cantor Fitzgerald Reaffirms Overweight Rating on AbbVie (ABBV)

AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know

Zacks

8 days ago

AbbVie (ABBV) Stock Falls Amid Market Uptick: What Investors Need to Know

Investing.com

8 days ago

Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Business Wire

8 days ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Argus Research

8 days ago

Technical Assessment: Bullish in the Intermediate-Term

AbbVie (ABBV): Assessing Valuation After Strong 28% Year-to-Date Share Price Jump

Simply Wall St.

9 days ago

AbbVie (ABBV): Assessing Valuation After Strong 28% Year-to-Date Share Price Jump

Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?

Zacks

9 days ago

Can Rinvoq and Skyrizi Sales Drive Another Strong Quarter for AbbVie?

Does AbbVie's Latest AI Partnership Signal More Room for Its 2025 Rally?

Simply Wall St.

9 days ago

Does AbbVie's Latest AI Partnership Signal More Room for Its 2025 Rally?

2 Profitable Stocks to Research Further and 1 We Avoid

StockStory

9 days ago

2 Profitable Stocks to Research Further and 1 We Avoid

MT Newswires

10 days ago

Sector Update: Health Care Stocks Advance Monday Afternoon

AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve

Zacks

10 days ago

AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve

MT Newswires

10 days ago

Sector Update: Health Care

MT Newswires

10 days ago

AbbVie Gains FDA Approval for Expanded Rinvoq Use in IBD Patients

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

PR Newswire

10 days ago

U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease

2 Dividend Stocks to Double Up on Right Now

Motley Fool

10 days ago

2 Dividend Stocks to Double Up on Right Now

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

PR Newswire

10 days ago

AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors

Hugel Inc. appoints Carrie Strom as Chief Executive Officer

PR Newswire

10 days ago

Hugel Inc. appoints Carrie Strom as Chief Executive Officer

Why Analysts See AbbVie’s Story Shifting After Strategic Wins and Growth Upgrades

Simply Wall St.

12 days ago

Why Analysts See AbbVie’s Story Shifting After Strategic Wins and Growth Upgrades

Global Protein Drugs Market to Reach $655.7 Billion by 2029

GlobeNewswire

13 days ago

Global Protein Drugs Market to Reach $655.7 Billion by 2029

MT Newswires

13 days ago

Goldman Sachs Adjusts AbbVie Price Target to $218 From $217, Maintains Neutral Rating

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

Zacks

13 days ago

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

MT Newswires

13 days ago

Piper Sandler Adjusts AbbVie Price Target to $284 From $231, Maintains Overweight Rating

What to Expect From AbbVie's Q3 2025 Earnings Report

Barchart

13 days ago

What to Expect From AbbVie's Q3 2025 Earnings Report

AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?

Zacks

14 days ago

AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025?

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

PR Newswire

14 days ago

SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

PR Newswire

14 days ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

MT Newswires

14 days ago

Cantor Fitzgerald Adjusts Price Target on AbbVie to $250 From $245, Maintains Overweight Rating

MT Newswires

14 days ago

JPMorgan Adjusts Price Target on AbbVie to $250 From $235, Maintains Overweight Rating

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

GlobeNewswire

14 days ago

Bispecific Antibodies Market - Global Forecast 2025-2032, Profiles of Key Players - F. Hoffmann-La Roche, Amgen, Janssen Biotech, Pfizer, AbbVie, Regeneron, MacroGenics, AstraZeneca, Merck, and Genmab

How pharma giant AbbVie holds leaders accountable for culture

Fortune

14 days ago

How pharma giant AbbVie holds leaders accountable for culture

Cramer’s ‘Absolute Favorite’ AbbVie Rises After Study Completions and Upgrade

Insider Monkey

15 days ago

Cramer’s ‘Absolute Favorite’ AbbVie Rises After Study Completions and Upgrade

AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts

Insider Monkey

15 days ago

AbbVie Inc. (ABBV) Starts Building $70 Million Expansion of Its AbbVie Bioresearch Centre in Worcester, Massachusetts

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

Zacks

16 days ago

Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

3 Dividend Stocks to Double Up On Right Now

Motley Fool

16 days ago

3 Dividend Stocks to Double Up On Right Now

Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know

Zacks

17 days ago

Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know

AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?

Zacks

17 days ago

AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?

MT Newswires

17 days ago

AbbVie Says Botox Met Primary Endpoint in Phase 2 Upper Limb Essential Tremor Trial

Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk

Zacks

17 days ago

Zacks Value Trader Highlights: Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

PR Newswire

17 days ago

AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor

How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results

Zacks

17 days ago

How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

PR Newswire

17 days ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

5 Large Cap Drug Stocks: Values or Traps?

Zacks

20 days ago

5 Large Cap Drug Stocks: Values or Traps?

MT Newswires

20 days ago

AbbVie Says $2.7 Billion in Costs Seen Cutting Q3 EPS by $1.50

How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment

Investor's Business Daily

20 days ago

How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment

Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?

Zacks

20 days ago

Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?

MT Newswires

20 days ago

TD Cowen Adjusts Price Target on AbbVie to $280 From $250, Maintains Buy Rating

Does AbbVie's (ABBV) Manufacturing Expansion Signal a Shift in Its Long-Term Growth Focus?

Simply Wall St.

20 days ago

Does AbbVie's (ABBV) Manufacturing Expansion Signal a Shift in Its Long-Term Growth Focus?

Bernstein Remains a Hold on AbbVie Inc. (ABBV)

Insider Monkey

20 days ago

Bernstein Remains a Hold on AbbVie Inc. (ABBV)

Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery

Insider Monkey

20 days ago

Bristol-Myers Squibb, Takeda, Astex Join AI Consortium to Train OpenFold3 for Accelerated Drug Discovery

2 Healthcare Stocks to Research Further and 1 Facing Challenges

StockStory

20 days ago

2 Healthcare Stocks to Research Further and 1 Facing Challenges

AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why

Zacks

21 days ago

AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why

MT Newswires

21 days ago

Calico, AbbVie's Investigational Kidney Disease Drug Gets FDA Fast Track Designation

Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

PR Newswire

21 days ago

Calico Life Sciences Announces U.S. FDA Fast Track Designation for Investigational Treatment of Autosomal Dominant Polycystic Kidney Disease

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

PR Newswire

21 days ago

AbbVie to Host Third-Quarter 2025 Earnings Conference Call

Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations

Newsfile

21 days ago

Defence Therapeutics Appoints Dr. Mark Lambermon as Head of Quality and Operations

AbbVie (ABBV) Advances Parkinson’s Treatment With Tavapadon NDA

Insider Monkey

21 days ago

AbbVie (ABBV) Advances Parkinson’s Treatment With Tavapadon NDA

Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance

Insider Monkey

21 days ago

Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance

Why AbbVie Stock Cruised to an Almost 6% Gain Today

Motley Fool

22 days ago

Why AbbVie Stock Cruised to an Almost 6% Gain Today

Why AbbVie (ABBV) Stock Is Trading Up Today

StockStory

22 days ago

Why AbbVie (ABBV) Stock Is Trading Up Today

AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability

Insider Monkey

22 days ago

AbbVie’s (ABBV) Dividend Track Record: A Testament to Stability

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi

GlobeNewswire

22 days ago

2025 Dermatology Treatment and Care Market Analysis Report with Impact Analysis of US Tariffs Featuring Novartis, Pfizer, Amgen, GSK, F. Hoffmann-La Roche, J&J, AbbVie, Merck, Bayer, Sanofi

MT Newswires

22 days ago

AbbVie Unit Signs Supply Deal With Vizient for Natrelle Breast Implants

MT Newswires

22 days ago

Climb Bio Names Dr. Susan Altschuller CFO

Natrelle® Awarded Supplier Agreement from Vizient

PR Newswire

22 days ago

Natrelle® Awarded Supplier Agreement from Vizient

MT Newswires

22 days ago

Bristol-Myers Squibb, Takeda Join Apheris' OpenFold3 Drug Discovery AI Model

Presbyopia Market Research Report 2025-2035 | FDA-Approved Eye Drops, Advanced IOLs and Personalized Medicine Drive Global Growth Amid Aging Population

GlobeNewswire

22 days ago

Presbyopia Market Research Report 2025-2035 | FDA-Approved Eye Drops, Advanced IOLs and Personalized Medicine Drive Global Growth Amid Aging Population

Bristol Myers, Takeda to pool data for AI-based drug discovery

Reuters

22 days ago

Bristol Myers, Takeda to pool data for AI-based drug discovery

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

Motley Fool

22 days ago

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

MT Newswires

23 days ago

AbbVie Submits Biologics License Application to FDA for Rare Blood Cancer Treatment

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

PR Newswire

23 days ago

AbbVie Submits Biologics License Application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) - an Investigational Antibody-Drug Conjugate (ADC) to Treat Rare Cancer with Limited Treatment Options

AbbVie Inc.(ABBV) Unit Expands Skin Solution Availability amid $5.2B Opportunity

Insider Monkey

23 days ago

AbbVie Inc.(ABBV) Unit Expands Skin Solution Availability amid $5.2B Opportunity

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

GlobeNewswire

24 days ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease

Zacks

24 days ago

AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease

MT Newswires

24 days ago

Sector Update: Health Care Stocks Edge Lower Monday Afternoon

MT Newswires

24 days ago

AbbVie Begins Construction of Manufacturing Facility in North Chicago

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

PR Newswire

24 days ago

AbbVie Breaks Ground on New North Chicago Active Pharmaceutical Ingredient Manufacturing Facility

MT Newswires

24 days ago

AbbVie Prices Ovarian Cancer Drug Elahere in UK That is Equal to US List Prices

AbbVie to launch ovarian cancer drug in UK at US price

Reuters

24 days ago

AbbVie to launch ovarian cancer drug in UK at US price

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

PR Newswire

24 days ago

AbbVie Announces UK Pricing Strategy for ELAHERE® (mirvetuximab soravtansine-gynx)

Assessing AbbVie (ABBV) Valuation After FDA Filing for New Parkinson’s Drug Tavapadon

Simply Wall St.

25 days ago

Assessing AbbVie (ABBV) Valuation After FDA Filing for New Parkinson’s Drug Tavapadon

Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.

Barrons.com

a month ago

Eli Lilly, Pfizer, Amgen Stocks Rise After Trump’s 100% Pharma Tariff Threat. Here’s Why.

Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?

Zacks

a month ago

Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?

Share on Social Networks: